MX2019006612A - Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). - Google Patents

Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).

Info

Publication number
MX2019006612A
MX2019006612A MX2019006612A MX2019006612A MX2019006612A MX 2019006612 A MX2019006612 A MX 2019006612A MX 2019006612 A MX2019006612 A MX 2019006612A MX 2019006612 A MX2019006612 A MX 2019006612A MX 2019006612 A MX2019006612 A MX 2019006612A
Authority
MX
Mexico
Prior art keywords
imidazo
pyrazine derivatives
pi3kdelta
inhibitors
disclosed
Prior art date
Application number
MX2019006612A
Other languages
English (en)
Inventor
Wang Zhiwei
Li Jing
Zhao Haibo
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2019006612A publication Critical patent/MX2019006612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe un compuesto de formula (I), o un estereoisomero del mismo, o una sal farmaceuticamente aceptable del mismo, y las composiciones farmaceuticas que comprenden los mismos; tambien se describe un metodo para tratar trastornos o enfermedades relacionadas con PI3Kd usando el compuesto descrito en este documento. (Ver fórmula I).
MX2019006612A 2016-12-07 2017-12-07 Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). MX2019006612A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Publications (1)

Publication Number Publication Date
MX2019006612A true MX2019006612A (es) 2019-08-01

Family

ID=62491736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006612A MX2019006612A (es) 2016-12-07 2017-12-07 Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).

Country Status (16)

Country Link
US (2) US11136323B2 (es)
EP (1) EP3551630A4 (es)
JP (2) JP7064495B2 (es)
KR (1) KR20190091339A (es)
CN (2) CN114805366A (es)
AU (2) AU2017372377B2 (es)
BR (1) BR112019011847A2 (es)
CA (1) CA3045959A1 (es)
EA (1) EA201991355A1 (es)
IL (2) IL266986B (es)
MX (1) MX2019006612A (es)
NZ (1) NZ754944A (es)
SG (1) SG10201912192RA (es)
TW (2) TWI762534B (es)
WO (1) WO2018103688A1 (es)
ZA (1) ZA201903286B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805366A (zh) 2016-12-07 2022-07-29 百济神州有限公司 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN111051312A (zh) * 2017-09-08 2020-04-21 百济神州有限公司 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
BR112023024594A2 (pt) * 2021-05-27 2024-02-06 Beigene Switzerland Gmbh Sais de um inibidor de pi3kdelta, formas cristalinas, métodos de preparação e seus usos
CA3231467A1 (en) * 2021-09-14 2023-03-23 Xiaomin Song Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
CA2756759C (en) * 2009-04-16 2017-11-07 Joaquin Pastor Fernandez Imidazopyrazines for use as kinase inhibitors
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
US9260435B2 (en) 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
BR112015029969A2 (pt) * 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
HUE056329T2 (hu) 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
CN114805366A (zh) * 2016-12-07 2022-07-29 百济神州有限公司 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN111051312A (zh) 2017-09-08 2020-04-21 百济神州有限公司 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂

Also Published As

Publication number Publication date
TW202233190A (zh) 2022-09-01
SG10201912192RA (en) 2020-02-27
CN110267959B (zh) 2022-05-27
IL290419B (en) 2022-10-01
TW201833113A (zh) 2018-09-16
WO2018103688A1 (en) 2018-06-14
JP2020500909A (ja) 2020-01-16
KR20190091339A (ko) 2019-08-05
TWI762534B (zh) 2022-05-01
AU2022203737A1 (en) 2022-06-23
EP3551630A1 (en) 2019-10-16
IL266986B (en) 2022-03-01
CN110267959A (zh) 2019-09-20
IL290419B2 (en) 2023-02-01
AU2017372377B2 (en) 2022-03-03
US11725012B2 (en) 2023-08-15
EP3551630A4 (en) 2020-07-15
CN114805366A (zh) 2022-07-29
JP2022090051A (ja) 2022-06-16
EA201991355A1 (ru) 2019-11-29
ZA201903286B (en) 2021-01-27
CA3045959A1 (en) 2018-06-14
AU2017372377A1 (en) 2019-07-18
JP7064495B2 (ja) 2022-05-10
IL266986A (en) 2019-07-31
US20220098202A1 (en) 2022-03-31
US20190367523A1 (en) 2019-12-05
IL290419A (en) 2022-04-01
NZ754944A (en) 2023-02-24
BR112019011847A2 (pt) 2019-10-29
US11136323B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
NZ766835A (en) Pharmaceutical compounds
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
MX2023001876A (es) Derivados de rapamicina.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
EA033689B9 (ru) Ингибиторы g12c kras
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
MX2021007247A (es) Derivados de rapamicina.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.